Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.97 -0.30 (-1.10%)
Streaming Delayed Price Updated: 10:46 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Recursion Pharma stock cleared a key performance benchmark Monday, with its Relative Strength Rating upgraded to 89 from 76 the day before. 
Via Investor's Business Daily
7 Safe Stocks to Rely on When the Market Swerves
As volatility and uncertainty continue, it remains a good time to add these seven safe stocks to your portfolio. 
Via InvestorPlace
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) showed a loss in earnings since Q1, totaling $17.35 million. Sales, on the other hand, increased by 2.57% to $123.47 million... 
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022
Via ACCESSWIRE
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
Via ACCESSWIRE
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
Amphastar Pharmaceuticals: Q2 Earnings Insights
  Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
Amphastar came in well above forecasts, while Syndax had fewer than expected losses. 
Via Investor's Business Daily
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
  
Via Benzinga
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
Amphastar Receives FDA Approval for Vasopressin
Via ACCESSWIRE
Amphastar Receives FDA Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
Prometheus Biosciences Stock Shows Rising Relative Strength
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before. 
Via Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.